Fig. 1: Study design and patient disposition.
From: Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial
a, Study design showing patients with confirmed AdvSM. b, Patient disposition. AdvSM, advanced systemic mastocytosis; mIWG-MRT-ECNM, modified International Working Group-Myeloproliferative Neoplasms Research and Treatment and European Competence Network on Mastocytosis; MCL, mast cell leukemia; QD, once daily.
